The Path to Therapeutic Furin Inhibitors: From Yeast Pheromones to SARS-CoV-2.

Abstract

The spurious acquisition and optimization of a furin cleavage site in the SARS-CoV-2 spike protein is associated with increased viral transmission and disease, and has generated intense interest in the development and application of therapeutic furin inhibitors to thwart the COVID-19 pandemic. This review summarizes the seminal studies that informed current efforts to inhibit furin. These include the convergent efforts of endocrinologists, virologists, and yeast geneticists that, together, culminated in the discovery of furin. We describe the pioneering biochemical studies which led to the first furin inhibitors that were able to block the disease pathways which are broadly critical for pathogen virulence, tumor invasiveness, and atherosclerosis. We then summarize how these studies subsequently informed current strategies leading to the development of small-molecule furin inhibitors as potential therapies to combat SARS-CoV-2 and other diseases that rely on furin for their pathogenicity and progression.

• Authors: Gary Thomas, Frédéric Couture, Anna Kwiatkowska
• Journal: International journal of molecular sciences (Int J Mol Sci) Vol. 23 Issue 7 (Mar 22 2022) ISSN: 1422-0067 [Electronic] Switzerland
• PMID: 35408793 (Publication Type: Journal Article, Review)

Chemical References

• Pheromones
• Spike Glycoprotein, Coronavirus
• spike protein, SARS-CoV-2
• Furin

Topics

• Furin (metabolism)
• Humans
• Pandemics
• Pheromones
• SARS-CoV-2
• Saccharomyces cerevisiae (metabolism)
• Spike Glycoprotein, Coronavirus
• COVID-19 Drug Treatment